Myriam Curet, Executive Vice President and Chief Medical Officer at Intuitive Surgical Inc (NASDAQ:ISRG), completed two stock sales on March 2 and March 3, 2026, disposing of a combined 4,853 shares of common stock for approximately $2.36 million.
The trades were executed in two separate transactions: on March 2 Curet sold 125 shares at $492.59 per share, and on March 3 she sold 4,728 shares at $487.18 per share. Per the filing details, the aggregate proceeds from these sales are around $2.36 million. Following these transactions, Curet retains direct ownership of 409 shares of Intuitive Surgical common stock held through a trust.
In conjunction with the March 2 sale, Curet exercised options to acquire 125 shares of Intuitive Surgical common stock at an exercise price of $208.90 per share, for a total exercise cost of $26,112. The filing notes these options are non-qualified stock options that vest in monthly installments according to the footnotes.
Trading plan and option terms
The disclosure states the sales were made under a Trading Plan implemented in compliance with SEC Rule 10b5-1; that plan is scheduled to expire on July 29, 2026. The filing also references a non-statutory stock option granted pursuant to the 2010 Incentive Award Plan, with vesting detailed as 7/48 one month after the date of grant and thereafter 1/48 each month.
Valuation context and ownership
Intuitive Surgical is valued at $176.65 billion and, at the time of the filing, its shares traded at $497.42 each. According to InvestingPro analysis cited in the filing, the stock appears overvalued relative to its Fair Value and is listed among companies on the Most Overvalued list.
Recent operating results and strategic moves
The company reported fourth-quarter revenue of $2.87 billion, a 19% year-over-year increase that topped both Stifel and consensus estimates of $2.72 billion. Earnings per share beat expectations, and Truist Securities highlighted a notable upside alongside a 90 basis point improvement in gross margin guidance for 2026.
In addition to financial results, Intuitive Surgical completed the acquisition of its distributors in Southern Europe, enabling direct operations in Italy, Spain, and Portugal.
Analyst reaction
- Stifel reiterated a Buy rating with a $670.00 price target.
- Truist Securities maintained a Buy rating and set a $650.00 target.
- Freedom Capital Markets upgraded the stock from Hold to Buy, citing optimism about the rollout of the da Vinci 5 surgical system.
- TD Cowen initiated coverage with a Buy rating and a $660.00 price target, describing Intuitive Surgical as a core MedTech holding with multiple growth vectors.
The filing and accompanying market commentary present a mixed picture: an insider sale of several thousand shares and the exercise of options, set against a backdrop of top-line outperformance, margin guidance improvement and positive analyst notes. For investors seeking more detailed valuation analysis and executive compensation context, the filing points to a comprehensive Pro Research Report available on InvestingPro.